Effects of systemic chemotherapy on the liver

Annals of Hepatology

Volumn 9, Issue 2, 2010, Pages 133-143

  Ramadori, Giuliano ^a   Cameron, Silke ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Chemotherapy; Host defence; Liver; Side effects

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ASPARAGINASE; BEVACIZUMAB; BUSULFAN; CAPECITABINE; CARMUSTINE; CETUXIMAB; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IMATINIB; IRINOTECAN; MERCAPTOPURINE; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PANITUMUMAB; RITUXIMAB; SORAFENIB; STREPTOZOCIN; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACNE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CARCINOMA; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CHOLESTASIS; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOTOXICITY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM PERFORATION; DNA METABOLISM; DNA REPLICATION; DNA SYNTHESIS; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; FATTY LIVER; FIBRINOLYSIS; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL TUMOR; GENETIC PREDISPOSITION; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOMAGNESEMIA; INTRAHEPATIC BILE DUCT; KIDNEY CARCINOMA; KUPFFER CELL; LIPID METABOLISM; LIPOPHILICITY; LIVER CELL CARCINOMA; LIVER CLEARANCE; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; LIVER NECROSIS; LIVER REGENERATION; LIVER TOXICITY; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; LUNG CANCER; MUCOSA INFLAMMATION; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NONALCOHOLIC FATTY LIVER; PARANEOPLASTIC SYNDROME; PORTAL VEIN THROMBOSIS; POSTOPERATIVE HEMORRHAGE; SIDE EFFECT; STEATOSIS; THROMBOEMBOLISM; THROMBOSIS; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VOMITING; WOUND HEALING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ENZYME ASSAY; FEMALE; LIVER; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REVIEW; RISK FACTOR; TOXIC HEPATITIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL ENZYME TESTS; DRUG-INDUCED LIVER INJURY; FATTY LIVER; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RISK FACTORS;

EID: 77956622858     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31651-5     Document Type: Article

References (86)

1. MacSween RNM, Desmet VJ, Roskams T, Scothorne RJ. Developmental anatomy and normal structure. In: MacSween RNM, Burt AD, Portmann BC (eds), eds. Pathology of the liver. Edinburgh: Churchill Livingstome; 2002, p. 1.
2. Roy-Chowdhury N, Roy-Chowdhury J. Liver Physiology and Energy Metabolism. In: Feldman M, Friedman LS, Brandt LJ (eds.). Gastrointestinal and Liver Disease. 2nd. Ed. Philadelphia; 2006, p. 1551.
3. Toth CA, Thomas P. Liver endocytosis and Kupffer cells. Hepatology 1992; 16(1): 255-266.
4. Rieder H, Meyer zum Buschenfelde KH, Ramadori G. Functional spectrum of sinusoidal endothelial liver cells. Filtration, endocytosis, synthetic capacities and intercellular communication. J Hepatol 1992; 15(1-2): 237-250.
5. Debatin KM. Cytotoxic drugs, programmed cell death, and the immune system: defining new roles in an old play. J Natl Cancer Inst 1997; 89(11): 750-751.
6. Parr L, Mossberg SM, Rosenzweig MW, Breslar EI, Clark G. An alteration in the nuclei of rat liver cells in starvation. 116th. Ed. 2005, p. 457-468.
7. Skullman S, Ihse I, Larsson J. Influence of malnutrition on regeneration and composition of the liver in rats. Acta ChirScand 1990; 156(10): 717-722.
8. Teoh NC, Farrell GC. Liver Disease Caused by Drugs. In: Fledman M, Friedman LS, Brandt LJ (eds.). Gastrointestinal and Liver Disease. 2nd. Ed. Philadelphia: Saunders Elsevier; 2006, p. 1807.
9. Wake K, Decker K, Kirn A, Knook DL, McCuskey RS, Bouwens L, et al. Cell biology and kinetics of Kupffer cells in the liver. Int Rev Cytol 1989; 118: 173-229.
10. Armbrust T, Ramadori G. Functional characterization of two different Kupffer cell populations of normal rat liver. J Hepatol 1996; 25(4): 518-528.
11. Armbrust T, Ramadori G. Mononuclear phagocytes of acutely injured rat liver abundantly synthesize and secrete fibronectin in contrast to Kupffer cells of normal liver. Bio-chem Biophys Res Commun 1995; 213(3): 752-758.
12. Bodenheimer HJr., Charland C, Leith J. Alteration of rat Kupffer cell function following mitomycin-C administration. J LeutocB/oM 1988 43(3): 265-270.
13. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33(1): 308-310.
14. Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez DLC. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33(1): 123-130.
15. Kaplowitz N. Drug induced liver disease. NY: Informa Health Care; 2007, p. 1.
16. DeLeve LD. Cancer Chemotherapy. In: Kaplowitz N, DeLe-ve LD (eds.). Drug-induced liver disease. 2nd. Ed. New York: Informa Health Care; 2007, p. 631-662.
17. Bearman SI. Veno-occlusive disease of the liver. Curr Opin Oncol 2000; 12(2): 103-109.
18. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22(1): 27-42.
19. de la Rubia J, Carral A, Montes H, Urquijo JJ, Sanz GF, Sanz MA. Successful treatment of hepatic veno-occlusive disease in a peripheral blood progenitor cell transplant patient with a transjugular intrahepatic portosystemic stent-shunt (TIPS). Haematologica 1996; 81(6): 536-539.
20. Norris S, Crosbie O, McEntee G, Traynor O, Nolan N, Mc-Cann S, et al. Orthotopic liver transplantation for veno-occlusive disease complicating autologous bone marrow transplantation. Transplantation 1997; 63(10): 1521-1524.
21. Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006 Feb; 33(1): 50-67.
22. Sitar DS. Human drug metabolism in vivo. Pharmacol Ther 1989; 43(3): 363-375.
23. Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat Res 1999 May; 436(3): 227-261.
24. Ferguson MJ, Ahmed FY, Cassidy J. The role of pro-drug therapy in the treatment of cancer. Drug Resist Updat 2001 Aug; 4(4): 225-232.
25. Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer 1998 Sep; 34(10): 1493-1499.
26. Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hase-gawa Y. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 2002 Feb; 24(1): 111-116.
27. Hoskins JM, Marcuello E, Altes A, Marsh S, Maxwell T, Van Booven DJ, et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 2008 Mar 15; 14(6): 1788-1796.
28. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocher-ginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004 Apr 15; 22(8): 1382-1388.
29. Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999 Oct; 5(10): 2672-2673.
30. Chenivesse X, Franco D, Brechot C. MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis. J Hepatol 1993 Jun; 18(2): 168-172.
31. Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 2008 May 1; 26(13): 2099-2105.
32. Yoo C. A cross-sectional study of imatinib serum levels in patients with advanced GIST. Abstract 161 ed. 2010.
33. Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 2005 Jul; 19(8): 1057-1063.
34. Field KM, Michael M. Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncol 2008 Dec; 9(12): 1181-1190.
35. Field KM, Dow C, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol 2008 Nov; 9(11): 1092-1101.
36. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 1998 Oct 22; 339(17): 1217-1227.
37. Kanel GC. Histopathology of drug-induced liver disease. In: Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 2nd edition ed. New York: Informa Health Care, 2007. 237-289.
38. Loganayagam A, Arenas-Hernandez M, Fairbanks L, Ross P, Sanderson JD, Marinaki AM. The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients. Cancer Chemother Pharmacol 2010 Jan; 65(2): 403-406.
39. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 1993 Dec; 11(12): 2386-2390.
40. Peppercorn PD, Reznek RH, Wilson P, Slevin ML, Gupta RK. Demonstration of hepatic steatosis by computerized to-mography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 1998 Jun; 77(11): 2008-2011.
41. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007 Mar; 94(3): 274-286.
42. Fleming GF, Schilsky RL, Schumm LP, Meyerson A, Hong AM, Vogelzang NJ, et al. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol 2003; 14(7): 1142-1147.
43. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45(4): 291-297.
44. Scheithauer W, McKendrick J, Begbie S, Borner M, Burns Wl, Bums HA, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14(12): 1735-1743.
45. Van CE, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19(21): 4097-4106.
46. Nikolic-Tomasevic Z, Jelic S, Cassidy J, Filipovic-Ljeskovic I, Tomasevic Z. Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis. Cancer Chemother Pharmacol 2005; 56(6): 594-602.
47. Doroshow JH, Synold TW, Gandara D, Mani S, Remick SC, Mulkerin D, et al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 2003; 30(4 Suppl. 15): 14-19.
48. Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24(31): 4983-4990.
49. Morris-Stiff G, Tan YM, Vauthey JN. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol 2008; 34(6): 609-614.
50. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Bre-zault C, Le CM, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15(3): 460-466.
51. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006 May 1; 24(13): 2065-2072.
52. Ma MK, McLeod HL. Lessons learned from the irinotecan metabolic pathway. Curr Med Chem 2003; 10(1): 41-49.
53. Meresse P, Dechaux E, Monneret C, Bertounesque E. Eto-poside: Discovery and medicinal chemistry. Current medicinal chemistry. 11th. Ed. Oak Park, IL, USA 1994: Bentham, 2004. 43-66.
54. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7(8): 2182-2194.
55. Raymond E, Boige V, Faivre S, Sanderink GJ, Rixe O, Verni-llet L, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20(21): 4303-4312.
56. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectabi-lity of hepatic colorectal metastases. J Am Coll Surg 2005; 200(6): 845-853.
57. Bums HA, Fields SM. Topoisomerase I inhibitors. An overview of the camptothecin analogs. Hematol Oncol Clin North Am 1994; 8(2): 333-355.
58. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22(4 Suppl. 11): 3-10.
59. Delauter BJ, Ramanathan RK, Egorin MJ, Stover LL, Zu-howski EG, Plunkett W, et al. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. Pharmacotherapy 2000; 20(10): 1204-1207.
60. Robinson K, Lambiase L, Li J, Monteiro C, Schiff M. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 2003; 48(9): 1804-1808.
61. Saif MW, Shahrokni A, Cornfeld D. Gemcitabine-induced liver fibrosis in a patient with pancreatic cancer. JOP 2007; 8(4): 460-467.
62. Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18(14): 2780-2787.
63. Asbury RF, Rosenthal SN, Descalzi ME, Ratcliffe RL, Arse-neau JC. Hepatic veno-occlusive disease due to DTIC. Cancer 1980; 45(10): 2670-2674.
64. Demetri GD, von MM, Blanke CD, Van den Abbeele AD, El-senberg B, Roberts PJ, et al. Efficacy and safety of imati-nib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347(7): 472-480.
65. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364(9440): 1127-1134.
66. Mindikoglu AL, Regev A, Bejarano PA, Martinez EJ, Jeffers LJ, Schiff ER. Imatinib mesylate (gleevec) hepatotoxicity. Dig Dis Sci 2007; 52(2): 598-601.
67. Miller AA, Murray DJ, Owzar K. Pharmakokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301. 25, abstr. 3538 ed. 2007.
68. Ortega J, Vigil CE, Chodkiewicz C. Current progress in targeted therapy for colorectal cancer. Cancer Control 2010; 17(1): 7-15.
69. Amado RG, Wolf M, Peeters M, Van CE, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26(10): 1626-1634.
70. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de BF, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27(5): 663-671.
71. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase 1MB trial of chemothe-rapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27(5): 672-680.
72. Moosmann N, Laessig D, Michaely HJ, Schulz C, Heinemann V. Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia. Onkologie 2007; 30(10): 509-512.
73. Brown-Glaberman U, Swart R, Dragovich T, Bracamonte E, Kurtin S, Stopeck A. Hepatic injury associated with bevacizumab use in metastatic breast and colon cancers: a review of two cases. Commun Oncol 2008; 5: 539-542.
74. Klinger M, Eipeldauer S, Hacker S, Herberger B, Tamandl D, Dorfmeister M, et al. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 2009; 35(5): 515-520.
75. Agarwal V, Sgouros J, Smithson J, Lodge J PA, Razack A, Campbell A, et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in a patient receiving bevacizumab for metastatic colorectal cancer: a case report. 2007; 2: 227.
76. Bilchik AJ, Poston G, Curley SA, Strasberg S, Saltz L, Adam R, et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 2005; 23(36): 9073-9078.
77. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243(1): 1-7.
78. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235(6): 759-766.
79. Abdalla EK, Vauthey JN. Chemotherapy prior to hepatic resection for colorectal liver metastases: helpful until harmful? Dig Surg 2008; 25(6): 421-429.
80. Hill J, Loeb E, MacLellan A, Hill NO, Khan A, King JJ. Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 1975; 59: 647-659.
81. Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park) 2005; 19: 1057-1063.
82. Aviles A, Herrera J, Ramos E, Ambriz R, Aguirre J, Pizzuto J. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med 1984; 108: 912-913.
83. Donelli MG, Zucchetti M, Munzone E, D'lncalci M, Crosig-nani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998; 34: 33-46.
84. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996; 14: 257-267.
85. Carreras E. Veno-occlusive disease of the liver after hemopoietic cell transplatnation. Eur J Haematol 2000; 64: 281-291.
86. Tran A, Housset C, Boboc B, Tourani JM, Carnot F, Berthe-lot P. Etosposid (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. J Hepa-to(1991; 12: 36-39.